Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Post-ASH 2022 AML highlights

11 January 2023 | Virtual Meeting

Post-ASH 2022 AML highlights

11 January 2023 | Virtual Meeting

Expert-led presentations & discussions on key abstracts in AML from ASH 2022

The Post-ASH 2022 iwAL Virtual Workshop was held on 11-12 January 2023, with a packed program covering acute myeloid leukemia (AML) on Day 1, and acute lymphoblastic leukemia (ALL) on Day 2. Both days featured a series of short presentations on selected abstracts from the 64th ASH Annual Meeting presented by experts with interactive panel discussions after each session.

Venetoclax regimens and combinations Novel targeted or immune therapies Novel therapies FLT3-mutated AML Chemotherapy/targeted therapies Immunotherapies and stem cell transplantation

Session 1: Venetoclax regimens and combinations

Naval Daver
Azacitidine, venetoclax & magrolimab in high-risk & R/R AML
Naval Daver The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Sameem Abedin
Lintuzumab-Ac225 in combination with intensive chemotherapy in R/R AML
Sameem Abedin Medical College of Wisconsin, Milwaukee, WI, United States
Courtney DiNardo
Long-term follow-up of the Phase III VIALE-A clinical trial
Courtney DiNardo The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Daniel Pollyea
ELN risk stratification & outcomes in patients with AML treated with VEN/AZA
Daniel Pollyea University of Colorado, Denver, CO, United States
Panel discussion

Session 2: Novel targeted or immune therapies

Ing Tiong
A prospective Phase II study of venetoclax & low dose Ara-C (VALDAC) in AML
Ing Tiong The Alfred Hospital and Monash University, Melbourne, Australia
Tapan Kadia
Venetoclax + CLIA as induction therapy for patients with ND AML & HR-MDS
Tapan Kadia The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Giovanni Marconi
Gimema AML1718 part 1: V-FLAI in the induction therapy of non-low-risk AML
Giovanni Marconi Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
Panel discussion

Session 3: Novel therapies

Kendra Sweet
Pivekimab sunirine, azacitidine & venetoclax in HR patients with R/R AML
Kendra Sweet H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Ghayas Issa
Revumenib in patients with KMT2A-rearranged or NPM1 mutant AML
Ghayas Issa The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Harry Erba
Phase I/II first-in-human study of ziftomenib in patients with R/R AML
Harry Erba Duke University, Durham, NC, United States
Panel discussion

Session 4: FLT3

Mark Levis
FLT3-ITD–specific MRD clearance is associated with improved overall survival
Mark Levis Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States
Chyn Chua
A sub-analysis of the ALLG INTERVENE study
Chyn Chua The Alfred Hospital and Monash University, Melbourne, Australia
Nicholas Short
Phase I/II study of azacitidine, venetoclax & gilteritinib for FLT3-mutated AML
Nicholas Short The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Panel discussion

Session 5: Chemotherapy/targeted therapies

Jad Othman
Genomic correlates of outcome: CPX-351 vs FLAG-Ida in HR AML and MDS
Jad Othman Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
Felicitas Thol
Gemtuzumab ozogamicin + intensive chemotherapy in NPM1-mutated AML
Felicitas Thol Hannover Medical School, Hannover, Germany
Panel discussion

Session 6: Immunotherapies and stem cell transplantation

Johannes Schetelig
Results from the randomized Phase III ASAP trial
Johannes Schetelig University Hospital TU Dresden, Dresden, Germany
Shernan Holtan
Post-transplant cyclophosphamide, tacrolimus & MMF for GvHD prophylaxis
Shernan Holtan University of Minnesota, Minneapolis, MN, United States
Amandeep Salhotra
Enasidenib as maintenance therapy after alloSCT in IDH2-mutated AML
Amandeep Salhotra City of Hope, Duarte, CA, United States
Alexander Perl
QuANTUM-First: Impact of alloSCT in first CR in addition to quizartinib
Alexander Perl University of Pennsylvania, Philadelphia, PA, United States
David Sallman
Ameli-01: A Phase I trial of UCART123v1.2 in patients with R/R CD123+ AML
David Sallman H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Sascha Haubner
Target densities in malignant & normal cells determine CAR-T cell efficacy
Sascha Haubner Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Marion Subklewe
The race is on: BiTE vs CAR-T as FLT3-directed immunotherapies in AML
Marion Subklewe LMU Hospital Munich, Munich, Germany
Panel discussion

The continued success of the iwAL meeting is in no small part due to the ongoing funding of supporters, allowing a unique opportunity for clinicians to be brought together to facilitate interactive and stimulating debates to help improve patient outcomes.
For more information about supporting future iwAL meetings and activities, please contact us here.

For the latest updates in AML, visit The AML Channel


The content of VJHemOnc is intended for healthcare professionals